A New Pathway for Sympathetic Cardioprotection in Heart Failure

Circulation Research

Volumn 117, Issue 7, 2015, Pages 592-595

  Simpson, Paul C ^a,b  

^a SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Editorials; epigenenomics; heart failure; methyl CpG binding protein 2; microRNAs; receptor, adrenergic

Indexed keywords

ANTAGOMIR; MESSENGER RNA; METHYL CPG BINDING PROTEIN 2; MICRORNA; MICRORNA 132; NORADRENALIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; ADRENERGIC RECEPTOR;

AORTA CONSTRICTION; CARDIOMYOPATHY; DOWN REGULATION; GENE CONTROL; GENE EXPRESSION; GENE REPRESSION; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HUMAN; LEFT VENTRICULAR ASSIST DEVICE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYMPATHETIC TONE; ADAPTATION; ANIMAL; BIOSYNTHESIS; GENETIC EPIGENESIS; METABOLISM; PHYSIOLOGY;

ADAPTATION, PHYSIOLOGICAL; ANIMALS; EPIGENESIS, GENETIC; HEART FAILURE; HUMANS; METHYL-CPG-BINDING PROTEIN 2; RECEPTORS, ADRENERGIC;

EID: 84941286474     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.115.307246     Document Type: Review

References (35)

1. Mayer SC, Gilsbach R, Preissl S, et al. Adrenergic repression of the epigenetic reader MeCP2 facilitates cardiac adaptation in chronic heart failure. Circ Res. 2015;117:622-633. doi: 10.1161/CIRCRESAHA.115.306721.
2. Carrillo ED, Escobar Y, González G, Hernández A, Galindo JM, Garciá MC, Sánchez JA. Posttranscriptional regulation of the ?2-subunit of cardiac L-type Ca2+ channels by MicroRNAs during long-term exposure to isoproterenol in rats. J Cardiovasc Pharmacol. 2011;58:470-478. doi: 10.1097/FJC.0b013e31822a789b.
3. Hou Y, Sun Y, Shan H, Li X, Zhang M, Zhou X, Xing S, Sun H, Chu W, Qiao G, Lu Y. ?-adrenoceptor regulates miRNA expression in rat heart. Med Sci Monit. 2012;18:BR309-BR314.
4. Ucar A, Gupta SK, Fiedler J, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;3:1078. doi: 10.1038/ncomms2090.
5. Jentzsch C, Leierseder S, Loyer X, Flohrschütz I, Sassi Y, Hartmann D, Thum T, Laggerbauer B, Engelhardt S. A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. J Mol Cell Cardiol. 2012;52:13-20. doi: 10.1016/j.yjmcc.2011.07.010.
6. Hong S, Lee J, Seo HH, Lee CY, Yoo KJ, Kim SM, Lee S, Hwang KC, Choi E. Na(+)-Ca(2+) exchanger targeting miR-132 prevents apoptosis of cardiomyocytes under hypoxic condition by suppressing Ca(2+) overload. Biochem Biophys Res Commun. 2015;460:931-937. doi: 10.1016/j. bbrc.2015.03.129.
7. Katare R, Riu F, Mitchell K, Gubernator M, Campagnolo P, Cui Y, Fortunato O, Avolio E, Cesselli D, Beltrami AP, Angelini G, Emanueli C, Madeddu P. Transplantation of human pericyte progenitor cells improves the repair of infarcted heart through activation of an angiogenic program involving micro-RNA-132. Circ Res. 2011;109:894-906. doi: 10.1161/CIRCRESAHA.111.251546.
8. Barile L, Lionetti V, Cervio E, Matteucci M, Gherghiceanu M, Popescu LM, Torre T, Siclari F, Moccetti T, Vassalli G. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res. 2014;103:530-541. doi: 10.1093/cvr/cvu167.
9. Lei Z, van Mil A, Brandt MM, Grundmann S, Hoefer I, Smits M, El Azzouzi H, Fukao T, Cheng C, Doevendans PA, Sluijter JP. MicroRNA-132/212 family enhances arteriogenesis after hindlimb ischaemia through modulation of the Ras-MAPK pathway. J Cell Mol Med. 2015;19:1994-2005. doi: 10.1111/jcmm.12586.
10. Zhao H, Wen G, Wen G, Huang Y, Yu X, Chen Q, Afzal TA, Luong le A, Zhu J, Shu Y, Zhang L, Xiao Q. MicroRNA-22 regulates smooth muscle cell differentiation from stem cells by targeting methyl CpGbinding protein 2. Arterioscler Thromb Vasc Biol. 2015;35:918-929. doi: 10.1161/ATVBAHA.114.305212.
11. Sadegh MK, Ekman M, Krawczyk K, Svensson D, Göransson O, Dahan D, Nilsson BO, Albinsson S, Uvelius B, Swärd K. Detrusor induction of miR-132/212 following bladder outlet obstruction: association with MeCP2 repression and cell viability. PLoS One. 2015;10:e0116784. doi: 10.1371/journal.pone.0116784.
12. Mann J, Chu DC, Maxwell A, Oakley F, Zhu NL, Tsukamoto H, Mann DA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology. 2010;138:705-14, 714.e1. doi: 10.1053/j.gastro.2009.10.002.
13. Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting Mecp2 via miR-22. PLoS One. 2014;9:e88685. doi: 10.1371/journal.pone.0088685.
14. Alvarez-Saavedra M, Carrasco L, Sura-Trueba S, Demarchi Aiello V, Walz K, Neto JX, Young JI. Elevated expression of MeCP2 in cardiac and skeletal tissues is detrimental for normal development. Hum Mol Genet. 2010;19:2177-2190. doi: 10.1093/hmg/ddq096.
15. Wanet A, Tacheny A, Arnould T, Renard P. miR-212/132 expression and functions: within and beyond the neuronal compartment. Nucleic Acids Res. 2012;40:4742-4753. doi: 10.1093/nar/gks151.
16. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550-559. doi: 10.1161/CIRCULATIONAHA.114.009625.
17. Whelan RS, Konstantinidis K, Xiao RP, Kitsis RN. Cardiomyocyte lifedeath decisions in response to chronic ?-adrenergic signaling. Circ Res. 2013;112:408-410. doi: 10.1161/CIRCRESAHA.113.300805.
18. Noma T, Lemaire A, Naga Prasad SV, Barki-Harrington L, Tilley DG, Chen J, Le Corvoisier P, Violin JD, Wei H, Lefkowitz RJ, Rockman HA. Beta-arrestin-mediated beta1-adrenergic receptor transactivation of the EGFR confers cardioprotection. J Clin Invest. 2007;117:2445-2458. doi: 10.1172/JCI31901.
19. Kim IM, Wang Y, Park KM, Tang Y, Teoh JP, Vinson J, Traynham CJ, Pironti G, Mao L, Su H, Johnson JA, Koch WJ, Rockman HA. ?-arrestin1-biased ?1-adrenergic receptor signaling regulates microRNA processing. Circ Res. 2014;114:833-844. doi: 10.1161/CIRCRESAHA.114.302766.
20. Tang Y, Wang Y, Park KM, Hu Q, Teoh JP, Broskova Z, Ranganathan P, Jayakumar C, Li J, Su H, Tang Y, Ramesh G, Kim IM. MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death. Cardiovasc Res. 2015;106:387-397. doi: 10.1093/cvr/cvv121.
21. Zhang X, Szeto C, Gao E, et al. Cardiotoxic and cardioprotective features of chronic ?-adrenergic signaling. Circ Res. 2013;112:498-509. doi: 10.1161/CIRCRESAHA.112.273896.
22. Okumura S, Fujita T, Cai W, et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J Clin Invest. 2014;124:2785-2801. doi: 10.1172/JCI64784.
23. Talan MI, Ahmet I, Xiao RP, Lakatta EG. AR agonists in treatment of chronic heart failure: long path to translation. J Mol Cell Cardiol. 2011;51:529-533. doi: 10.1016/j.yjmcc.2010.09.019.
24. Woo AY, Song Y, Xiao R, Zhu W. Biased ?2-adrenoceptor signalling in heart failure: pathophysiology and drug discovery [published online ahead of print October 8, 2014]. Br J Pharmacol. doi: 10.1111/bph.12965.
25. Fajardo G, Zhao M, Urashima T, Farahani S, Hu DQ, Reddy S, Bernstein D. Deletion of the ?2-adrenergic receptor prevents the development of cardiomyopathy in mice. J Mol Cell Cardiol. 2013;63:155-164. doi: 10.1016/j.yjmcc.2013.07.016.
26. Belge C, Hammond J, Dubois-Deruy E, et al. Enhanced expression of ?3-adrenoceptors in cardiac myocytes attenuates neurohormone-induced hypertrophic remodeling through nitric oxide synthase. Circulation. 2014;129:451-462. doi: 10.1161/CIRCULATIONAHA.113.004940.
27. Huang Y, Wright CD, Merkwan CL, Baye NL, Liang Q, Simpson PC, O'Connell TD. An alpha1A-adrenergic-extracellular signal-regulated kinase survival signaling pathway in cardiac myocytes. Circulation. 2007;115:763-772. doi: 10.1161/CIRCULATIONAHA.106.664862.
28. Jensen BC, O'Connell TD, Simpson PC. Alpha-1-adrenergic receptors: targets for agonist drugs to treat heart failure. J Mol Cell Cardiol. 2011;51:518-528. doi: 10.1016/j.yjmcc.2010.11.014.
29. McCauley MD, Wang T, Mike E, Herrera J, Beavers DL, Huang TW, Ward CS, Skinner S, Percy AK, Glaze DG, Wehrens XH, Neul JL. Pathogenesis of lethal cardiac arrhythmias in Mecp2 mutant mice: implication for therapy in Rett syndrome. Sci Transl Med. 2011;3:113ra125. doi: 10.1126/scitranslmed.3002982.
30. De Felice C, Maffei S, Signorini C, Leoncini S, Lunghetti S, Valacchi G, D'Esposito M, Filosa S, Della Ragione F, Butera G, Favilli R, Ciccoli L, Hayek J. Subclinical myocardial dysfunction in Rett syndrome. Eur Heart J Cardiovasc Imaging. 2012;13:339-345. doi: 10.1093/ejechocard/jer256.
31. Perrino C, Naga Prasad SV, Mao L, Noma T, Yan Z, Kim HS, Smithies O, Rockman HA. Intermittent pressure overload triggers hypertrophyindependent cardiac dysfunction and vascular rarefaction. J Clin Invest. 2006;116:1547-1560. doi: 10.1172/JCI25397.
32. Crozatier B, Ventura-Clapier R. Inhibition of hypertrophy, per se, may not be a good therapeutic strategy in ventricular pressure overload: other approaches could be more beneficial. Circulation. 2015;131:1448-1457. doi: 10.1161/CIRCULATIONAHA.114.013895.
33. Schiattarella GG, Hill JA. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation. 2015;131:1435-1447. doi: 10.1161/CIRCULATIONAHA.115.013894.
34. Harrison DE. V. Life span as a biomarker. 2015: https://www.jax.org/research-and-faculty/research-labs/the-harrison-lab/gerontology/lifespan-as-a-biomarker. Accessed August 28, 2015.
35. Lyst MJ, Bird A. Rett syndrome: a complex disorder with simple roots. Nat Rev Genet. 2015;16:261-275. doi: 10.1038/nrg3897.